临床试验 (2 articles)

DeepMind AlphaFold 3 Pioneers AI-Designed Cancer Drug in Clinical Trial: AI Pharma's Qualitative Leap from Prediction to Creation

DeepMind's AlphaFold 3 has achieved a milestone with its first AI-designed cancer drug DM-301 entering Phase I clinical trials, marking the transition of AI in drug discovery from auxiliary tool to independent creator.

AI Accelerating Drug Development: A Revolution from Lab to Clinic, or Reality's Bottleneck?

While AI promises to compress traditional drug development from 10-15 years to potentially just a few years, with companies like Insilico Medicine achieving clinical trials in 18 months, skeptics point to persistent clinical trial challenges and regulatory barriers that question whether this represents true revolution or mere hype.